myelin

In a poster session at the Annual meeting of the Society for Neuroscience in Washington, ENDECE Neural presented pre-clinical results showing their lead drug – NDC-1308 – induces remyelination in mouse models of demyelination disease, such as Multiple Sclerosis. Loss of myelin is the main characteristic of a group…

In a study entitled “Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination” the authors report to have found a new protein, Del-1, that reduces the severity of multiple sclerosis disease in a mouse model of the disease. The…

Loss of myelin, the fatty protective sheath around nerve fibers, is a characteristic of multiple sclerosis (MS). A new magnetic resonance imaging (MRI) study by a team of researchers has determined that people with MS lose myelin in the gray matter of their brains, and that the amount of loss…

As researchers continue to develop a clearer understanding of the underlying causes of multiple sclerosis (MS), it is becoming increasingly apparent that the future of treating the disease is likely to center on neural protection and a reversal of the demyelination process that strips away the critical insulation…

The University of California, San Francisco (UCSF) initiated a clinical trial to evaluate the antihistamine clemastine fumarate, manufactured by Novartis as Tavist, for its efficacy in treating multiple sclerosis patients. The laboratory of Dr. Jonah Chan, a professor of neurology at UCSF, used a high-throughput method to identify Tavist…

Stem therapy to treat multiple sclerosis may benefit greatly from a new study published in Proceedings of the National Academy of Sciences by the laboratory of Fraser Sim, Ph.D., assistant professor of Pharmacology and Toxicology at University of Buffalo’s School of Medicine and Biomedical Sciences. Dr.